Loading…

Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment

AIM: To evaluate anti-hepatitis B virus (HBV) activity and cytotoxicity of interferon-α, (IFN-3,) and tumor ne- crosis factor-α (TNF-α) following lamivudine treatment of HepG2.2.15 cells. METHODS: HepG2.2.15 cells were treated with 2 pmol/L lamivudine for 16 d (lamivudine group), cultured for 10 d,...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2012-07, Vol.18 (27), p.3617-3622
Main Authors: Shi, Hong, Lu, Lu, Zhang, Ning-Ping, Zhang, Shun-Cai, Shen, Xi-Zhong
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM: To evaluate anti-hepatitis B virus (HBV) activity and cytotoxicity of interferon-α, (IFN-3,) and tumor ne- crosis factor-α (TNF-α) following lamivudine treatment of HepG2.2.15 cells. METHODS: HepG2.2.15 cells were treated with 2 pmol/L lamivudine for 16 d (lamivudine group), cultured for 10 d, followed by 5 ng/ml TNF-α and 1000 U/mL IFN-γ, for 6 d (cytokine group), or treated with 2 ~tmol/L lami- vudine for 10 d followed by 5 ng/mL TNF-α and 1000 U/mL IFN-γ, for 6 d (sequential group), or cultured without additions for 16 d (control group). Intracellular DNA was extracted from 3 ×10^ HepG2.2.15 cells from each group. The extracted DNA was further purified with mung bean nuclease to remove HBV relaxed circu- lar DNA that may have remained. Both HBV covalently closed circular DNA (cccDNA) and HBV DNA were exam- ined with real-time polymerase chain reaction. The titers of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were quantified with enzyme-linkedimmunosorbent assay. Cell viability was measured with the cell counting kit-8 assay. RESULTS: Compared to lamivudine alone (22.63%±0.12%), both sequential (51.50% ± 0.17%, P = 0.034) and cytokine treatment (49.66% ± 0.06%, P = 0.041) showed a stronger inhibition of HBV cccDNA; the dif- ference between the.sequential and cytokine groups was not statistically significant (51.50% ± 0.17% vs 49.66% ± 0.06%, P = 0.88). The sequential group showed less inhibition of HBV DNA replication than the lamivudine group (67.47% ±0.02% vs 82.48% ± 0.05%, P = 0.014); the difference between the sequen- tial and cytokine groups was not statistically significant (67.47% ± 0.02% vs 57.45% ± 0.07%, P = 0.071). The levels of HBsAg and HBeAg were significantly de- creased in the sequential treatment group compared to the other groups [HBsAg: 3.48 ± 0.04 (control), 3.09 ± 0.08 (lamivudine), 2.55± 0.13 (cytokine), 2.32 ± 0.08 (sequential), P = 0.042 for each between-group comparison; HBeAg 3.48 ± 0.01 (control), 3.08 ± 0.08 (lamivudine), 2.57 ± 0.15 (cytokine), 2.34 ± 0.12 (se- quential), P = 0.048 for each between-group compari- son]. Cell viability in the cytokine group was reduced to 58.03% ± 8.03% compared with control cells (58.03% ± 8.03% vs 100%, P = 0.000). Lamivudine pretreat- ment significantly reduced IFN-γ, ± TNF-αmediated toxicity of HepG2.2.15 cells [85.82% =1= 5.43% (sequen- tial) vs 58.03% ± 8.03% (cytokine), P = 0.002]. CONCLUSION: Sequential treatment overcame the lower ability of lamivudine
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v18.i27.3617